Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 5/20 | 0.38 |
| ▸ | HTR1A | P08908 | 3/20 | 0.32 |
| ▸ | HTR6 | P50406 | 3/20 | 0.32 |
| ▸ | HTR7 | P34969 | 2/20 | 0.32 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.31 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.31 |
| ▸ | ENPP2 | Q13822 | 4/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7014922 | 0.96 | TACR1 (0.38) | TACR1HTR1AHTR6HTR7ITGB3 | |
| SCHEMBL7017321 | 0.85 | TACR1 (0.40) | TACR1ITGB3ITGA2BENPP2 | |
| SCHEMBL7013608 | 0.83 | CCR5 (0.38) | TACR1 | |
| SCHEMBL7109118 | 0.79 | CCR5 (0.37) | TACR1 | |
| SCHEMBL17140591 | 0.76 | TACR1 (0.55) | TACR1ENPP2 | |
| SCHEMBL7016683 | 0.75 | ELANE (0.40) | TACR1 | |
| SCHEMBL7013914 | 0.71 | ITGB3 (0.37) | TACR1ITGB3ITGA2BENPP2 | |
| SCHEMBL17140557 | 0.68 | ENPP2 (0.42) | TACR1ENPP2 | |
| SCHEMBL17140717 | 0.64 | ENPP2 (0.42) | TACR1ENPP2 | |
| SCHEMBL3642681 | 0.64 | MEN1 (0.40) | HTR1AHTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030187023-A1 | Sulfone derivatives, process for their production and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2003-10-02 | — | — | US | disclosed |
| EP-1302462-A1 | SULFONE DERIVATIVES, PROCESS FOR THEIR PRODUCTION AND USE THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2003-04-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030187023-A1 | Sulfone derivatives, process for their production and use thereof | SULT1E1, RRS1, SHH | TACR1 1484/4885HTR1A 2113/4885HTR6 1194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.